news
Potential anti-COVID-19 nasal spray developed by researchers
A new nasal spray with ingredients already approved for use in humans could be used to protect people against COVID-19.
List view / Grid view
Formulation
Filter the results
Whitepapers/App Notes/Posters
Fact sheet: CFS 1200® capsule filling and sealing machine
At Lonza, we have developed our CFS 1200® capsule filling and sealing machine as part of our Lonza Engine™ portfolio. Used with our Capsugel® capsules, pharmacies can automate this process to optimise operations and accuracy. This fact sheet will introduce you to its handling and sealing capabilities, key benefits, performance…
Whitepapers/App Notes/Posters
Interactive PDF: Risk mitigation and quality requirements interactive tool
Risk mitigation interactive tool to guide you through the challenges and quality requirements of your bio-manufacturing process.
webinar
How to master raw material ID testing in 2021
11 November 2020 | By Thermo Fisher Scientific
In this webinar taking place on 9 December, we explore the evolving role of handheld and portable instruments to drive quality improvements and manufacturing success in 2021. Reserve your free virtual seat today!
article
Cannabinoid series: developing a synthetic CBD tablet
Aubrey Dan explains how EmpowerPharm developed its synthetic CBD tablet and why a novel formulation could help combat a range of indications.
article
How a global network provides a genuine advantage
When a client gets an opportunity to expand rapidly, it takes a global partner to pull it off without a hitch.
article
Science and risk-based specification setting for excipients
Reducing unnecessary regulatory burden relating to excipients is important for any pharmaceutical manufacturer. In this article, Sunil Kumar Nataraj, Bastiaan Dickhoff and Kalyan Janjanam discuss a rational basis for controlling and specifying conflicting excipient attributes to avoid potentially tedious and complex regulatory processes.
article
Approval of regulatory starting materials
There are significant interpretational differences between the European Medicines Agency (EMA) and US Food and Drug Administration (FDA)’s guidance on active pharmaceutical ingredient (API) starting materials. In this article, Dave Elder explores the ambiguity in guidance from both agencies and addresses why industry struggles to identify and justify starting materials…
news
First-in-human trial to study remestemcel-L as Crohn’s disease therapy launched
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
article
Expert view: High viscosity, high volume biologics call for new delivery device designs
The increasing use of subcutaneous administration stems from the significant advances in biological drug development, as well as the rising trend of self-administration.
news
Chemspec Digital 2020: pave the way for the recovery of the fine and speciality chemicals industry
Hosted online from 11 – 12 November, Chemspec Digital 2020 provides an interactive networking event for the fine and speciality chemicals community. From all over the world, industry experts will have the opportunity to meet, conduct business, discover innovative substances and learn about the latest trends and developments.
news
Nanoformed formulation of piroxicam to enter Phase I trials
The first-in-human clinical trial of nanoformed piroxicam will begin in late 2020, with results expected by mid-2021.
video
On-demand webinar: BioPhorum raw materials risk assessments
Introduction to BioPhorum (BPOG) raw materials risk assessments tool and an overview on risk assessment regulations for raw materials.
webinar
Liquid-filled hard capsules: A flexible tool for rapid access to the clinic with poorly soluble and/or highly potent compounds
21 October 2020 | By Lonza Pharma & Biotech
Watch our on-demand webinar to learn about liquid-filled hard capsule technology has a proven record for addressing complex active pharmaceutical ingredient (API) formulation challenges, including bioavailability enhancement.
news
Inhaled antibody treatment for COVID-19 shows success in pre-clinical trials
Researchers have developed a monoclonal antibody called AR-711 that is highly neutralising against COVID-19 in an inhaled formulation.